Last updated: June 25, 2026
Executive summary: In Takeda Pharmaceuticals America, Inc. v. Apotex, Inc., No. 2:21-cv-12998 (D.N.J.), Takeda sued Apotex in a Hatch-Waxman patent case framed around an FDA ANDA submission. The case caption confirms the parties and filing posture, but no docket-level filings, asserted patents, ANDA drug/product details, claim construction, Markman results, or final judgment are provided in the input. Without those core litigation facts, a complete and accurate litigation summary and patent-exclusivity analysis cannot be produced.
What patents were asserted in Takeda v. Apotex (2:21-cv-12998)?
Answer: Not available from the provided information.
Which Orange Book patents were at issue?
Answer: Not available from the provided information.
What drug product does the case cover (ANDA reference listed drug and proposed generic)?
Answer: Not available from the provided information.
When was the lawsuit filed and what procedural events matter most?
Answer: Not available from the provided information beyond the case number and filing year (2021).
Complaint filing date
Answer: Not available from the provided information.
Answer and counterclaims
Answer: Not available from the provided information.
Schedule milestones (Markman, summary judgment, trial)
Answer: Not available from the provided information.
Any stays under 21 U.S.C. § 355(j)(5)(B)(iii)
Answer: Not available from the provided information.
Was this case a Paragraph IV ANDA challenge?
Answer: Not available from the provided information.
Which ANDA and what Paragraph IV notice date
Answer: Not available from the provided information.
Was the court action limited to 35 U.S.C. § 271(e)(2) infringement?
Answer: Not available from the provided information.
What did Takeda allege and what were Apotex’s defenses?
Answer: Not available from the provided information.
Infringement theory (literal infringement vs. doctrine of equivalents)
Answer: Not available from the provided information.
Invalidity defenses (anticipation, obviousness, written description, enablement)
Answer: Not available from the provided information.
Non-infringement defenses (claim construction-dependent, off-target differences)
Answer: Not available from the provided information.
How did claim construction and evidentiary rulings affect the case outcome?
Answer: Not available from the provided information.
Markman ruling
Answer: Not available from the provided information.
Claim construction impact on infringement/invalidity
Answer: Not available from the provided information.
Expert testimony and technical disputes
Answer: Not available from the provided information.
What was the result: settlement, dismissal, or final judgment?
Answer: Not available from the provided information.
Were the asserted patents found invalid or not infringed?
Answer: Not available from the provided information.
Was there a consent judgment or stipulated dismissal with prejudice?
Answer: Not available from the provided information.
Were there non-monetary terms (design-around, launch delay, license terms)?
Answer: Not available from the provided information.
What is the exclusivity and patent-expiration timeline impact for generic launch?
Answer: Not available from the provided information because the asserted patents, listed drug, and expiration dates are not provided.
When do the key Orange Book patents expire?
Answer: Not available from the provided information.
When do the 30-month stay and any triggering events end?
Answer: Not available from the provided information.
Does pediatric exclusivity extend patent or exclusivity end dates?
Answer: Not available from the provided information.
How does Takeda’s patent estate compare with Apotex’s litigation risk in this case?
Answer: Not available from the provided information.
Strength indicators typically evaluated (remaining claim scope, prior litigation history, PTO reexams)
Answer: Not available from the provided information.
Anticipated generic launch risk if Takeda’s asserted claims fail
Answer: Not available from the provided information.
Which other companies were likely involved in the same ANDA/patent landscape?
Answer: Not available from the provided information.
Co-defendants or related litigations in D.N.J.
Answer: Not available from the provided information.
Other Paragraph IV filings for the same reference listed drug
Answer: Not available from the provided information.
What is the FDA regulatory status and Orange Book listing status?
Answer: Not available from the provided information.
Is the ANDA approved, tentative approved, or pending?
Answer: Not available from the provided information.
Are there distribution or launch carve-outs tied to settlement?
Answer: Not available from the provided information.
Key Takeaways
No defensible litigation summary or patent exclusivity analysis can be completed from the provided input. The required case specifics, including asserted patents, the referenced drug/ANDA identity, procedural posture, and case outcome, are not present.
FAQs
- What is the typical scope of claims under 35 U.S.C. § 271(e)(2) in Takeda v. Apotex-type Hatch-Waxman cases?
- How do 30-month stays interact with patent expiration in D.N.J. Paragraph IV litigations?
- What claim-construction factors most often determine infringement outcomes in ANDA patent cases?
- How do settlement structures (license vs. covenants vs. stipulated injunctions) affect generic launch timelines?
- What Orange Book listing changes can signal resolution of ANDA litigation?
References
- Takeda Pharmaceuticals America, Inc. v. Apotex, Inc., No. 2:21-cv-12998 (D.N.J.).
